Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats

Nakano, Toshiaki; Cheng, Yu‐Fan; Lai, Chia-Yun; Hsu, Li-Wen; Chang, Yen‐Hsiang; Deng, Jia; Huang, Yu-Zhu; Honda, Hiroyuki; Chen, Kuang‐Den; Wang, Chih-Chi; Chiu, King-Wah; Jawan, Bruno; Eng, Hock‐Liew; Goto, Shigeru; Chen, Chao‐Long

doi:10.1016/j.jhep.2010.11.028

Cited by 133 publications

(131 citation statements)

References 32 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…In the only animal study, Nakano et al . investigated the impact of sunlight therapy on the progression of NAFLD in rats 32. In the present study, phototherapy ameliorated IR and hepatic steatosis caused by a choline‐deficient and iron‐supplemented l ‐amino acid defined (CDAA) diet.…”

Section: Discussionmentioning

confidence: 84%

Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial

et al. 2017

View full text Add to dashboard Cite

Background and AimDeficiency of vitamin D may be related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the effect of vitamin D supplementation in patients with NAFLD.MethodsA total of 81 patients with NAFLD with normal or raised (n = 47) serum alanine aminotransferase (ALT) having vitamin D deficiency were randomized prospectively. Group 1 (n = 51) received lifestyle modifications and a single injection of vitamin D (600 000 U) (standard medical treatment [SMT] + vitamin D) and group 2 (n = 30) received lifestyle modifications (SMT) for 6 months. The primary objective of this study was to assess the improvement in insulin resistance (IR) and serum ALT (in patients with raised ALT) and the secondary objective was to assess the change in cytokine profile in the SMT + vitamin D group.ResultsAfter 6 months, significant improvement in serum levels of ALT was observed in the SMT + vitamin D group when compared to the SMT group (ALT [87 ± 48 and 59 ± 32 IU/mL, P < 0.001] vs [64 ± 35 and 62 ± 24 IU/mL, P = 0.70]). Mean insulin levels and homeostasis model assessment‐IR remained unchanged at 6 months in the SMT + vitamin D group while there was a significant increase in mean insulin and homeostasis model assessment‐IR in the SMT group. SMT + vitamin D group had significant increase in mean serum levels of adiponectin (836 ± 309 and 908 ± 312 (pg/mL), P = 0.018) compared with the baseline; tumor necrosis factor‐α levels decreased from baseline but the change was not significant.ConclusionPatients with NAFLD given vitamin D in addition to lifestyle modifications have significant improvement in serum ALT and serum adiponectin levels.

show abstract

Section: Discussionmentioning

confidence: 84%

Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In rats fed a western diet, vitamin D depletion exacerbated histological features of NASH as well as increasing markers of oxidative stress and IR (106). Vitamin D depletion is also associated with increased inflammation (107) and phototherapy to restore vitamin D levels reduced hepatic TG accumulation and improved markers of inflammation and fibrosis (107).…”

Section: Vitamin Dmentioning

confidence: 99%

Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders

Hazlehurst

Tomlinson

2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease spanning from simple benign steatosis to steatohepatitis with fibrosis and scarring that can eventually lead to cirrhosis. Its prevalence is rising rapidly and is developing into the leading indication for liver transplantation worldwide. Abnormalities in endocrine axes have been associated with NALFD, including hypogonadism, hypothyroidism, GH deficiency and hypercortisolaemia. In some instances, correction of the endocrine defects has been shown to have a beneficial impact. While in patients with type 2 diabetes the association with NAFLD is well established and recognised, there is a more limited appreciation of the condition among common endocrine diseases presenting with hormonal excess or deficiency. In this review, we examine the published data that have suggested a mechanistic link between endocrine abnormalities and NAFLD and summarise the clinical data endorsing these observations.

show abstract

“…As such, replacing inadequate vitamin D levels may induce biochemical and histological benefits to the host. Preclinical studies, notably that of Nakano et al [22] reported a beneficial effect of phototherapy on NAFLD progression in rats, accompanied by increased serum concentrations of vitamin D metabolites.…”

Section: Introductionmentioning

confidence: 99%

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Papapostoli

Lammert

Stokes

2016

JGLD

View full text Add to dashboard Cite

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. A meta-analysis has confirmed decreased serum 25-hydroxyvitamin D levels in NAFLD patients. This intervention study investigates whether vitamin D correction ameliorates hepatic steatosis. Methods: We prospectively recruited 40 patients from an outpatient liver clinic with vitamin D deficiency (serum 25-hydroxyvitamin D < 20 ng/ml). Controlled attenuation parameter (CAP) during transient elastography quantified hepatic steatosis. Patients with significant liver fat accumulation were included, which was defined by a CAP value ≥ 280 dB/m. Patients received 20,000 IU vitamin D/week for six months, while vitamin D status, liver function tests (LFTs), CAP and body composition were monitored. Results: The cohort comprised 47.5% women (age 54.9 ± 12.1 years; BMI 29.5 ± 3.0 kg/m2). Mean serum vitamin D level was 11.8 ± 4.8 ng/ml. CAP decreased significantly from baseline (330 ± 32 vs. 307 ± 41 dB/m) during supplementation (P = 0.007). A mean CAP reduction relative to baseline was demonstrated at four weeks and three and six months: -5.3 ± 13.8%; -6.0 ± 14.6% and -6.4 ± 13.0%, respectively. During these time points, restoration of serum vitamin D levels was observed (34.6 ± 12.9, 36.3 ± 10.2, 34.8 ± 9.8 ng/ml; P < 0.0001). Liver function tests and body composition remained unchanged. Conclusions: Hepatic steatosis, as assessed by CAP, significantly improves after only 4 weeks of vitamin D correction. Hepatic steatosis is a dynamic process, that can be monitored in the short-term using such non-invasive methods. Abbreviations: ALT: alanine aminotransferase; ANOVA: analysis of variance; AP: alkaline phosphatase; AST: aspartate aminotransferase; CAP: controlled attenuation parameter; CRP: C-reactive protein; FFA: free fatty acids; γ-GT: gamma-glutamyl transpeptidase; ITT: intention-to-treat; LFT: liver function test; LSM: liver stiffness measurement; NAFLD: non-alcoholic fatty liver disease; PPAR-γ: peroxisome proliferator-activated receptor gamma; PP: per protocol; PTH: parathyroid hormone; VDR: vitamin D receptor

show abstract

Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats

Cited by 133 publications

References 32 publications

Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial

Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial

Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Contact Info

Product

Resources

About